Cytokinetics, Incorporated
CYTK
Updated: 24/09/2026, 18:13:29
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
No summaries found.
- Share price
- $65.28
- Market cap
- $8.12B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Robert I. Blum
- Employees
- 673
- IPO date
- 26/04/2004
- Beta
- 0.36
- Last dividend
- $0.00
- Day range
- $64.89 – $66.15
- 52-week range
- $47.22 – $88.31
- 1-day performance
- -0.80%
- 1-year performance
- 38.25%
- Current drawdown (1Y)
- -26.08%
- CIK
- 0001061983
- CUSIP
- 23282W605
- ISIN
- US23282W6057
- Created
- 07/12/2025, 03:31:29
- Last update
- 24/09/2026, 18:13:29
Track Cytokinetics, Incorporated with an AI analyst
See which prediction-market events move CYTK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 05:58:30
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
GlobeNewsWire • STOCK • 01/06/2026, 09:30:00
Cytokinetics to Participate in June Investor Conferences
GlobeNewsWire • STOCK • 27/05/2026, 18:00:00
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha • STOCK • 27/05/2026, 17:47:04
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewsWire • STOCK • 20/05/2026, 18:00:00
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
GlobeNewsWire • STOCK • 08/05/2026, 12:51:00
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewsWire • STOCK • 07/05/2026, 01:00:00
Cytokinetics (NASDAQ: CYTK) Q1 Revenue Soars on MYQORZO Success Despite Loss
Market Data • Market Data • 06/05/2026, 02:07:44
Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript
Seeking Alpha • STOCK • 06/05/2026, 00:41:17
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Seeking Alpha • STOCK • 05/05/2026, 15:41:19
Cytokinetics heart disease drug meets main goals in late-stage study
Reuters • STOCK • 05/05/2026, 09:35:17
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
GlobeNewsWire • STOCK • 05/05/2026, 09:30:00